

MODA applies pre payment claims edits to diagnosis criteria and criteria for maximum units. Prior Authorization criteria *do not apply* for this policy.



# **Pluvicto<sup>®</sup> (lutetium Lu 177 vipivotide tetraxetan)** (Intravenous)

Document Number: IC-0665

Last Review Date: 07/05/2022 Date of Origin: 04/04/2022 Dates Reviewed: 04/2022, 07/2022

## I. Length of Authorization

Coverage will be provided for 5 months (4 doses) and may be renewed to provide for 2 additional doses. The total number of doses authorized cannot exceed 6 doses.

## II. Dosing Limits

- A. Quantity Limit (max daily dose) [NDC Unit]:
  - N/A

#### B. Max Units (per dose and over time) [HCPCS Unit]:

• 200 mCi (7.4 GBq = 200 mCi) every 6 weeks for a total of 6 doses

## III. Initial Approval Criteria<sup>1</sup>

Coverage is provided in the following conditions:

• Patient is at least 18 years of age; AND


## Universal Criteria 1,2

• Patient will receive concurrent treatment with a GnRH-analog or has had a bilateral orchiectomy; **AND** 

## Prostate Cancer † <sup>1-4</sup>

- Patient has metastatic castration-resistant prostate cancer (mCRPC); AND
- Patient has at least one prostate-specific membrane antigen (PSMA)-positive lesion and/or predominately PSMA-positive disease; **AND**
- Patient has no dominant PSMA-negative metastatic lesions; AND
- Patient has been previously treated with an androgen receptor-directed therapy (e.g., enzalutamide, abiraterone, etc.) AND taxane-based chemotherapy
- FDA Approved Indication(s); Compendia recommended indication(s); Orphan Drug

Moda Health Plan, Inc. Medical Necessity Criteria



Page 1/4

## IV. Renewal Criteria<sup>1</sup>

Coverage can be renewed based upon the following criteria:

- Patient continues to meet universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), performance status, etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: myelosuppression (e.g., anemia, thrombocytopenia, leukopenia, neutropenia), severe renal toxicity, etc.; **AND**
- Disease response with treatment as defined by stabilization of disease or at least a partial response; **AND**
- Patient has not received more than 6 doses total

## V. Dosage/Administration<sup>1</sup>


Indication	Dose
mCRPC	The recommended Pluvicto dosage is 7.4 GBq (200 mCi) intravenously every 6 weeks (up to 10 weeks for toxicities) for up to 6 doses, or until disease progression, or unacceptable toxicity.
	• Select patients with previously treated mCRPC for treatment with Pluvicto using LOCAMETZ or another approved PSMA-11 imaging agent based on PSMA expression in tumors.
	(Pluvicto is a radiopharmaceutical; handle with appropriate safety measures to minimize radiation exposure. Use waterproof gloves and effective radiation shielding when handling Pluvicto. Radiopharmaceuticals, including Pluvicto, should be used by or under the control of healthcare providers who are
	qualified by specific training and experience in the safe use and handling of radiopharmaceuticals, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals.)

## VI. Billing Code/Availability Information

## HCPCS code:

- A9699 Radiopharmaceutical, therapeutic, not otherwise classified NDC:
- Pluvicto 1,000 MBq/mL (27 mCi/mL) of lutetium Lu 177 vipivotide tetraxetan 30 mL singledose vial containing 7.4 GBq (200 mCi) [370 MBq/mL (10 mCi/mL)] : 69488-0010-XX

Moda Health Plan, Inc. Medical Necessity Criteria



Page 2/4

## VII. References

- 1. Pluvicto [package insert]. Milburn, NJ; Advanced Accelerator Applications USA, Inc; March 2022. Accessed June 2022.
- 2. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) lutetium lu 177 vipivotide tetraxetan. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc. To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed June 2022.
- 3. Referenced with permission from the NCCN Drugs & Biologics Compendium (NCCN Compendium®) for Prostate Cancer 4.2022. National Comprehensive Cancer Network, 2022. The NCCN Compendium® is a derivative work of the NCCN Guidelines®. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, and NCCN GUIDELINES® are trademarks owned by the National Comprehensive Cancer Network, Inc." To view the most recent and complete version of the Compendium, go online to NCCN.org. Accessed June 2022.
- Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep 16;385(12):1091-1103. Doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.

## **Appendix 1 – Covered Diagnosis Codes**

ICD-10	ICD-10 Description	
C61	Malignant neoplasm of prostate	
Z85.46	Personal history of malignant neoplasm of prostate	


## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Articles (LCAs) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <a href="http://www.cms.gov/medicare-coverage-database/search.aspx">http://www.cms.gov/medicare-coverage-database/search.aspx</a>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions				
Jurisdiction	Applicable State/US Territory	Contractor		
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC		
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC		

Moda Health Plan, Inc. Medical Necessity Criteria



Medicare Part B Administrative Contractor (MAC) Jurisdictions			
Jurisdiction	Applicable State/US Territory	Contractor	
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)	
6	MN, WI, IL	National Government Services, Inc. (NGS)	
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.	
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)	
N (9)	FL, PR, VI	First Coast Service Options, Inc.	
J (10)	TN, GA, AL	Palmetto Government Benefit Administrators, LLC	
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC	
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.	
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)	
15	КҮ, ОН	CGS Administrators, LLC	

Moda Health Plan, Inc. Medical Necessity Criteria

Proprietary & Confidential

© 2021 Magellan Health, Inc.

